If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
KE Holdings Inc. (BEKE)
RedBall Acquisition Corp. (RBAC.U)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NavSight Holdings (NSH.U)
dMY Technology Group II (DMYD.U)
Duck Creek Technologies, Inc. (DCT)
CureVac B.V. (CVAC)
Dragoneer Growth Opportunities (DGNR.U)
Northern Genesis Acquisition (NGA.U)
Inhibrx, Inc. (INBX)
Harmony Biosciences Holdings, Inc. (HRMY)
Priced IPO
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
More companies

Lantern Pharma (LTRN)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from their targeted oncology therapies. Their portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that they are developing with the assistance of their A.I. platform and their biomarker driven approach. Their strategy is to both develop new drug candidates using their RADR® platform and other machine learning driven methodologies, and to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted in development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant for the disease or condition under study as measured against the comparator treatment used in the relevant clinical testing) or for strategic reasons by the owner or development team responsible for the compound.
Panna Sharma David R. Margrave
Employees Founded
7 2013


Address: 1920 McKinney Avenue, 7th Floor, Dallas, TX 75201, US

Telephone: (972) 277-1136

Web page:

IPO information

Expected Date 6/11/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $96.5
Revenues (MM) $0
Net Income (Loss) (MM) $-2.45


What do you think will happen with the LTRN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 1.6
Shares Revised (MM) 1.8
Expected offer amount (MM) $26.3
Realized offer amount(MM) $27
ThinkEquity (a division of Fordham Financial Management)
Dougherty & Company LLC

Sector: Healthcare

Tweets about $LTRN

Tweets volume:

RT volume:


Google Trends Stats